Forcefield Therapeutics
UK - LondonBiotechnology
Focus: Forcefield Therapeutics is a UK-based public biotech company specializing in cardiomyocyte protective drugs for metabolic diseases. The company operates with minimal visible pipeline disclosure and limited active hiring.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
3
Should You Work at Forcefield Therapeutics?
AI assessmentEarly-stage career move suitable only for mission-driven scientists willing to accept low visibility and limited transparency on pipeline depth.
Why Work Here
- Focused therapeutic area (cardiomyocyte protection) offers deep specialization opportunity in an unmet metabolic disease space.
- Public company status provides equity upside and regulatory milestone visibility.
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Forcefield Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.